Skip to main content

Table 1 Pathological and clinical data of the arrayed prostate cancers

From: Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer

  No. of patients (%)
Study cohort on TMA (n = 12,427) Biochemical relapse among categories
Follow-up (mo)
n 11,665 (93.9%) 2769 (23.7%)
Mean 62.9
Median 50.0
Age (y)
≤50 334 (2.7%) 81 (24.3%)
51–59 3061 (24.8%) 705 (23%)
60–69 7188 (58.2%) 1610 (22.4%)
≥70 1761 (14.3%) 370 (21%)
Pretreatment PSA (ng/ml)
<4 1585 (12.9%) 242 (15.3%)
4–10 7480 (60.9%) 1355 (18.1%)
10–20 2412 (19.6%) 737 (30.6%)
>20 812 (6.6%) 397 (48.9%)
pT stage (AJCC 2002)
pT2 8187 (66.2%) 1095 (13.4%)
pT3a 2660 (21.5%) 817 (30.7%)
pT3b 1465 (11.8%) 796 (54.3%)
pT4 63 (0.5%) 51 (81%)
Gleason grade
≤3 + 3 2848 (22.9%) 234 (8.2%)
3 + 4 6679 (53.8%) 1240 (18.6%)
3 + 4 Tert.5 433 (3.5%) 115 (26.6%)
4 + 3 1210 (9.7%) 576 (47.6%)
4 + 3 Tert.5 646 (5.2%) 317 (49.1%)
≥4 + 4 596 (4.8%) 348 (58.4%)
pN stage
pN0 6970 (91%) 1636 (23.5%)
pN+ 693 (9%) 393 (56.7%)
Surgical margin
Negative 9990 (81.9%) 1848 (18.5%)
Positive 2211 (18.1%) 853 (38.6%)
  1. Percent in the column “Study cohort on TMA” refers to the fraction of samples across each category. Percent in column “Biochemical relapse among categories” refers to the fraction of samples with biochemical relapse within each parameter in the different categories. NOTE: Numbers do not always add up to 12,427 in different categories because of cases with missing data. Abbreviation: AJCC, American Joint Committee on Cancer